Kinins and Cardiovascular Diseases

ISSN: 1873-4316 (Online)
ISSN: 1389-2010 (Print)


Volume 15, 12 Issues, 2014


Download PDF Flyer




Current Pharmaceutical Biotechnology

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 112th of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Zeno Foldes-Papp
Visiting Professor of Medical Biochemistry
HELIOS Clinical Center of Emergency Medicine
Department for Internal Medicine
Alte-Koelner-Strasse 9
D-51688 Koeln-Wipperfuerth
Germany


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.511
5 - Year: 2.817

Kinins and Cardiovascular Diseases

Author(s): Jin Bo Su

Affiliation: INSERM U660, Faculte de Medecine, 8 rue du General Sarrail, 94010 Creteil, France.

Abstract

Kinins are synthesized from their precursors by different enzymes and participate in the regulation of cardiovascular function through bradykinin (BK) B1 and B2 receptors. They modulate blood coagulation by exerting antithrombotic and profibrinolytic actions. By activating B2 receptors that results in the release of nitric oxide and prostacyclin, kinins inhibit vascular smooth muscle growth and neointima formation, which may play an inhibitory role on the atherosclerosis development, while through the activation of B1 receptors, they may play a deleterious role in this disease. Kinins are potent endogenous vasodilators that are involved in the regulation of coronary vascular tone. However, due to their metabolic characteristics, these peptides act mainly as an autocrine/paracrine factor to locally regulate blood perfusion of organs. By modulating cellular energy metabolism and myocardial oxygen consumption, they protect cardiac and vascular endothelial function in myocardial ischemia and heart failure. Finally, mounting evidence indicates that kinins are involved in the actions of some drugs actually used in the treatment of cardiovascular diseases such as angiotensinconverting enzyme inhibitors and angiotensin AT1 receptor antagonists. Taken together, the kinin system constitutes a potential therapeutic target for cardiovascular diseases. Experiments in animals attempted to explore the kinin system as a therapeutic means, including the mobilization of endogenous kinins using pharmacological agents, searching BK analogs with long-acting properties and gene therapies. However, the potential values of the kinin system have not been taken into consideration in clinical practice for cardiovascular indications.

Keywords: Kinin system, Vasomotion, Hemostasis, Atherosclerosis, Myocardial ischemia, Heart failure, Angiotensinconverting enzyme inhibitors, Angiotensin AT1 receptor antagonists

Purchase Online Order Reprints Order Eprints Rights and Permissions

  
  



Article Details

Volume: 12
Issue Number: 26
First Page: 3423
Last Page: 3435
Page Count: 13
DOI: 10.2174/138161206778194051
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science